The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP

Li, Jing Jing; Ding, Ya; Li, Dan Dan; Peng, Rui; Feng, Gong Kan; Zeng, Yi Xin; Zhu, Xiao Feng; Zhang, Xiao Shi

doi:10.4161/cbt.8.20.9439

Cited by 11 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The A549/CDDP cell line is a cell model which is most commonly used to study platinumresistant of lung cancer. 10,11 Since resistant cell line and its parental cell line are homologous, they are often used in the comparative studies for drug resistance. [12][13][14] Among the profile generated by miRNA microarray, miR-21, with well reported oncogenic activity in various cancers, is highly expressed in the platinum-resistant A549/CDDP cell line compared with its parent A549 cell line.…”

Section: Resultsmentioning

confidence: 99%

MiRNA-21

Gao

Lü

Liu

et al. 2012

Cancer Biology & Therapy

127

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

MiRNA-21

Gao

Lü

Liu

et al. 2012

Cancer Biology & Therapy

127

View full text Add to dashboard Cite

“…ERCC1 is a key factor involved in nuclear excision repair (NER) for platinum induced adducts [13]. There is observation of platinum resistance in lung cancer A549 cells lines with high expression of ERCC1 [14], and increased clinical evidence that overexpression of ERCC1 in NSCLC inhibits platinum efficacy. In addition to ERCC1 negative tumors appear to benefit from cisplatin based chemotherapy, it also gains benefit from overall survival as a prognostic factor [2,15,16].…”

Section: Discussionmentioning

confidence: 99%

Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy

Leng

Chen

Xian

et al. 2012

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundThe aim of this study was to investigate prognostic value of excision repair cross-complementing 1 (ERCC1), BCL2-associated athanogene (BAG-1), the breast and ovarian cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III β-tubulin (TUBB3) in patients with non-small cell lung cancer (NSCLC) who received platinum- based adjuvant chemotherapy.MethodsMessenger RNA expressions of these genes were examined in 85 tumor tissues and 34 adjacent tissue samples using semi-quantitative RT-PCR. The expressions of these five genes were analyzed in relation to chemotherapy and progression-free survival (PFS) and overall survival (OS). Seventy-four patients were enrolled into chemotherapy.ResultsPatients with ERCC1 or BAG-1 negative expression had a significantly longer PFS (P = 0.001 and P = 0.001) and OS (P = 0.001 and P = 0.001) than those with positive expression. Patients with negative ERCC1 and BAG-1 expression benefited more from platinum regimen (P = 0.001 and P = 0.002). Patients with BRCA1 negative expression might have a longer OS (P = 0.052), but not PFS (P = 0.088) than those with BRCA1 positive expression. A significant relationship was observed between the mRNA expression of ERCC1 and BAG-1 (P = 0.042). In multivariate analysis, ERCC1 and BAG-1 were significantly favorable factors for PFS (P = 0.018 and P = 0.017) and OS (P = 0.027 and P = 0.022).ConclusionsERCC1 and BAG-1 are determinants of survival after surgical treatment of NSCLC, and its mRNA expression in tumor tissues could be used to predict the prognosis of NSCLC treated by platinum.

show abstract

“…The human lung adenocarcinoma cell lines A549 and A549/DDP (cisplatin-resistant variant) were graciously provided by Dr. Xiaofeng Zhu, Sun Yat-sen University [ 23 ]. The lung cancer cell lines NCI-H460 (H460) and H460/DDP (cisplatin-resistant variant) were graciously provided by Dr. Liwu Fu, Sun Yat-sen University [ 24 ].…”

Section: Methodsmentioning

confidence: 99%

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis

Yue

Zhou

et al. 2014

J Transl Med

View full text Add to dashboard Cite

BackgroundPlatinum-based chemotherapy improves survival among patients with non-small cell lung cancer (NSCLC), but the efficiency is limited due to resistance. In this study, we aimed to identify the expression of Aurora-A and its correlation with cisplatin resistance and prognosis in NSCLC.MethodsWe used immunohistochemical analysis to determine the expression of Aurora-A protein in 102 NSCLC patients treated by surgery and adjuvant cisplatin-based chemotherapy. The prognostic significances were assessed by Kaplan-Meier survival estimates and Cox models. The potential role of Aurora-A in the regulation of cisplatin resistance in NSCLC cells was examined by transfections using expression vector and small interfering RNA or using small-molecule inhibitors.ResultsAurora-A expression was significantly associated with clinical stage (p = 0.018), lymph node metastasis (p = 0.038) and recurrence (p = 0.005), and was an independent prognostic parameter in multivariate analysis. High level of Aurora-A expression predicted poorer overall survival (OS) and progression-free survival (PFS). In vitro data showed that Aurora-A expression was elevated in cisplatin-resistant lung cancer cells, and overexpression or knockdown of Aurora-A resulted in increased or decreased cellular resistance to cisplatin. Furthermore, inhibition of Aurora-A reversed the migration ability of cisplatin-resistant cells.ConclusionsThe current findings suggest that high Aurora-A expression is correlated with cisplatin-based chemotherapeutic resistance and predicts poor patient survival in NSCLC. Aurora-A might serve as a predictive biomarker of drug response and therapeutic target to reverse chemotherapy resistance.

show abstract

The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP

Cited by 11 publications

References 56 publications

MiRNA-21

MiRNA-21

Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis

Contact Info

Product

Resources

About